In 2022, DIA events are returning to a face-to-face format. DIA is committed to delivering a safe and secure conference to all participants. This means, for this event all in-person participants must comply with our Event Safety Code of Conduct, which requires either vaccination, certificate of recovery, or proof of inability to be vaccinated alongside a valid PCR test. Please click here for more information regarding our Event Safety Code of conduct.
Innovative Therapies, including cell and gene and ATMPs, are becoming one of the main focus areas for the industry. Developing those very complex therapies fast, authorizing, making them accessible, delivering and ensuring safety for patients throughout the life cycle of these products are the main challenges in this field. On the road towards solutions, join the collaborative efforts of key stakeholders and experts in the area of market access from industry, HTA bodies, payers, regulators and academia in the fourth edition of the DIA-EUCOPE Workshop focusing on lessons learned and applications for the new entrants. In the series of plenary and break-out sessions, we will share specific case studies review gained experience, and discuss approaches that can be taken to improve market access of these therapies.